Literature DB >> 22467533

Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.

Uri Kopylov1, Shomron Ben-Horin, Oded Zmora, Rami Eliakim, Lior H Katz.   

Abstract

BACKGROUND: Anti-tumor necrosis factor (TNF) antibodies are efficacious in patients with Crohn's disease (CD) but the influence of these medications on surgical outcomes in CD patients has been frequently debated. The aim was to evaluate the impact of preoperative treatment with anti-TNF antibodies on postoperative complications in CD patients undergoing abdominal surgery.
METHODS: A systematic review and meta-analysis of comparative cohort studies was performed assessing postoperative complication rates in CD patients who were treated with anti-TNF antibodies within 3 months before surgery versus patients who were not. The primary outcome was overall complication rate within 1 month of surgery. Secondary outcomes included the rate of infectious and noninfectious complications. The quality of studies was assessed based on selection of patients and controls, comparability of the study groups, and assessment of outcomes. Odds ratios (OR) with 95% confidence intervals (CIs) were computed.
RESULTS: A total of eight studies including 1641 patients were included in our meta-analysis. Preoperative infliximab therapy in CD patients undergoing abdominal surgery was associated with a trend toward an increased rate of total complications (OR 1.72, 95% CI, 0.93-3.19). Anti-TNF treatments were associated with a modestly increased risk of infectious complications (OR 1.50, 95% CI 1.08-2.08), mostly remote from the surgical site (OR 2.07 95% CI 1.30-3.30) and with a trend toward a higher rate of noninfectious complications (OR 2.00, 95% CI 0.89-4.46).
CONCLUSION: Preoperative infliximab treatment is associated with an increased risk of postoperative infectious complications, mostly nonlocal. A trend toward an increased risk of noninfectious and overall complications was also observed.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467533     DOI: 10.1002/ibd.22954

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  47 in total

Review 1.  [Multimodal oncological therapy concepts, chemotherapy and immunosuppressive drugs: effects on surgical morbidity and mortality].

Authors:  A K Berger; D Jäger
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

Review 2.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

3.  GM6001 Increases Anastomotic Leakage following Colonic Obstruction Possibly by Impeding Epithelialization.

Authors:  Martin Rehn; Peter-Martin Krarup; Lise H Christensen; Jakob B Seidelin; Magnus S Ågren; Ingvar Syk
Journal:  Surg Infect (Larchmt)       Date:  2015-07-14       Impact factor: 2.150

4.  A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn's disease.

Authors:  Kiyoshi Maeda; Hisashi Nagahara; Masatsune Shibutani; Hiroshi Otani; Katsunobu Sakurai; Takahiro Toyokawa; Hiroaki Tanaka; Naoshi Kubo; Kazuya Muguruma; Noriko Kamata; Hirokazu Yamagami; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-10-16       Impact factor: 2.549

5.  Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study.

Authors:  Takayuki Yamamoto; Antonino Spinelli; Yasuo Suzuki; Rogerio Saad-Hossne; Fabio Vieira Teixeira; Idblan Carvalho de Albuquerque; Rodolff Nunes da Silva; Ivan Folchini de Barcelos; Ken Takeuchi; Akihiro Yamada; Takahiro Shimoyama; Lorete Maria da Silva Kotze; Matteo Sacchi; Silvio Danese; Paulo Gustavo Kotze
Journal:  United European Gastroenterol J       Date:  2015-08-06       Impact factor: 4.623

6.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

7.  The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.

Authors:  Cheryl Lau; Marla Dubinsky; Gil Melmed; Eric Vasiliauskas; Dror Berel; Dermot McGovern; Andrew Ippoliti; David Shih; Stephan Targan; Phillip Fleshner
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

Review 8.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

9.  Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis.

Authors:  Peter Waterland; Thanos Athanasiou; Heena Patel
Journal:  World J Gastrointest Surg       Date:  2016-03-27

10.  Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era".

Authors:  Yi Li; Luca Stocchi; Yuanyi Rui; Ganglei Liu; Emre Gorgun; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.